Skip to main content
Premium Trial:

Request an Annual Quote

Avellino Labs Gets CLIA Certification

NEW YORK — Avellino Labs said today that its Menlo Park, California facility has received CLIA certification, enabling the company to receive and process samples for its AvaGen test for keratoconus and corneal dystrophies.

AvaGen is a next-generation sequencing-based test designed to analyze 1,000 variants across 75 genes to determine the risk of keratoconus, as well as over 70 TGFBI mutations of the transforming growth factor beta induced — or TGFBI — gene for detecting the presence of corneal dystrophies.

With the CLIA certification, Silicon Valley-based Avellino said it plans to being a limited rollout of AvaGen this quarter, with nationwide availability expected in 2020.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.